These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Serum guanidino compound levels and clearances in uremic patients treated with continuous ambulatory peritoneal dialysis. De Deyn PP; Marescau B; Swartz RD; Hogaerth R; Possemiers I; Lowenthal A Nephron; 1990; 54(4):307-12. PubMed ID: 2325795 [TBL] [Abstract][Full Text] [Related]
5. Serum guanidino compound levels and the influence of a single hemodialysis in uremic patients undergoing maintenance hemodialysis. De Deyn P; Marescau B; Lornoy W; Becaus I; Van Leuven I; Van Gorp L; Lowenthal A Nephron; 1987; 45(4):291-5. PubMed ID: 3587469 [TBL] [Abstract][Full Text] [Related]
6. Gas chromatographic determination of guanidino compounds in uremic patients using glyoxal as derivatizing reagent. Majidano SA; Khuhawar MY J Chromatogr Sci; 2012 May; 50(5):380-6. PubMed ID: 22392369 [TBL] [Abstract][Full Text] [Related]
7. High-performance liquid chromatographic measurement of guanidino compounds of clinical importance in human urine and serum by pre-column fluorescence derivatization using benzoin. Kai M; Miyazaki T; Ohkura Y J Chromatogr; 1984 Nov; 311(2):257-66. PubMed ID: 6520173 [TBL] [Abstract][Full Text] [Related]
8. Guanidino compound levels in brain regions of non-dialyzed uremic patients. De Deyn PP; Marescau B; D'Hooge R; Possemiers I; Nagler J; Mahler C Neurochem Int; 1995 Sep; 27(3):227-37. PubMed ID: 8520461 [TBL] [Abstract][Full Text] [Related]
9. Serum guanidino compound levels in uremic pediatric patients treated with hemodialysis or continuous cycle peritoneal dialysis. Correlations between nerve conduction velocities and altered guanidino compound concentrations. De Deyn PP; Robitaille P; Vanasse M; Qureshi IA; Marescau B Nephron; 1995; 69(4):411-7. PubMed ID: 7777105 [TBL] [Abstract][Full Text] [Related]
10. Guanidino compound metabolism in rats subjected to 20% to 90% nephrectomy. Levillain O; Marescau B; de Deyn PP Kidney Int; 1995 Feb; 47(2):464-72. PubMed ID: 7536856 [TBL] [Abstract][Full Text] [Related]
11. Improved Gas Chromatographic Determination of Guanidino Compounds Using Isovaleroylacetone and Ethyl Chloroformate as Derivatizing Reagents. Zounr RA; Khuhawar MY; Jahangir TM; Alamgir M Anal Sci; 2016; 32(2):141-6. PubMed ID: 26860556 [TBL] [Abstract][Full Text] [Related]
12. Significance of guanidino compounds in non-dialyzed patients with chronic renal failure. Ikezaki N Nihon Jinzo Gakkai Shi; 1990 Mar; 32(3):283-90. PubMed ID: 2355664 [TBL] [Abstract][Full Text] [Related]
13. An automated technique for the analysis of plasma guanidino acids, and some findings in chronic renal disease. Shainkin R; Berkenstadt Y; Giat Y; Berlyne GM Clin Chim Acta; 1975 Apr; 60(1):45-50. PubMed ID: 236102 [TBL] [Abstract][Full Text] [Related]
14. Automatic system for the assay of guanidino compounds to assess uremic status. Nohara Y; Hanai T; Suzuki J; Matsumoto G; Iinuma F; Kubo H; Kinoshita T; Watanabe M Biol Pharm Bull; 2000 Sep; 23(9):1015-20. PubMed ID: 10993196 [TBL] [Abstract][Full Text] [Related]
15. Gas chromatographic analysis of guanidino compounds in sera and urine of uremic patients using glyoxal and ethyl chloroformate as derivatizing reagents. Majidano SA; Khuhawar MY Anal Sci; 2013; 29(2):221-6. PubMed ID: 23400288 [TBL] [Abstract][Full Text] [Related]
16. High-performance liquid chromatographic analysis of guanidino compounds using ninhydrin reagent. II. Guanidino compounds in blood of patients on haemodialysis therapy. Hiraga Y; Kinoshita T J Chromatogr; 1985 Aug; 342(2):269-75. PubMed ID: 4055949 [TBL] [Abstract][Full Text] [Related]
17. Guanidino compounds that are increased in cerebrospinal fluid and brain of uremic patients inhibit GABA and glycine responses on mouse neurons in cell culture. De Deyn PP; Macdonald RL Ann Neurol; 1990 Nov; 28(5):627-33. PubMed ID: 2135950 [TBL] [Abstract][Full Text] [Related]
18. Guanidino compounds in serum and cerebrospinal fluid of non-dialyzed patients with renal insufficiency. De Deyn PP; Marescau B; Cuykens JJ; Van Gorp L; Lowenthal A; De Potter WP Clin Chim Acta; 1987 Jul; 167(1):81-8. PubMed ID: 3665089 [TBL] [Abstract][Full Text] [Related]
19. Plasma concentration and urinary excretion of guanidine derivatives in normal subjects and patients with renal failure. Sawynok J; Dawborn JK Clin Exp Pharmacol Physiol; 1975; 2(1):1-15. PubMed ID: 1126056 [TBL] [Abstract][Full Text] [Related]
20. Convulsive action and toxicity of uremic guanidino compounds: behavioral assessment and relation to brain concentration in adult mice. D'Hooge R; Pei YQ; Marescau B; De Deyn PP J Neurol Sci; 1992 Oct; 112(1-2):96-105. PubMed ID: 1469446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]